Sotorasib in Advanced KRAS p.G12C-Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP)

被引：0

作者：

Awad, M. M. ^{[1
]}

Pelizzari, G. ^{[2
]}

Stevenson, J. ^{[3
]}

Majem, M. ^{[4
]}

Ferreira, C. Gil ^{[5
]}

Petty, W. ^{[6
]}

Arriola, E. ^{[7
]}

De Castro, J. ^{[8
]}

Morbeck, I. ^{[9
]}

Bauman, J. ^{[10
]}

Toschi, L. ^{[11
]}

Zer, A. ^{[12
]}

Metro, G. ^{[13
]}

Kalmadi, S. ^{[14
]}

Azkarate, A. ^{[15
]}

Xia, C. ^{[16
]}

Meloni, A. ^{[16
]}

Obiozor, C. ^{[16
]}

Hsu, H. ^{[16
]}

Varrieur, T. ^{[16
]}

Ardito-Abraham, C. ^{[16
]}

Maimon, N. ^{[17
]}

Novello, S. ^{[18
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Azienda Sanitaria Univ Friuli Cent, Dipartimento Oncol Udine, Udine, Italy

[3] Cleveland Clin, Dept Hematol & Med Oncol, Taussig Canc Inst, Cleveland, OH USA

[4] Hosp Santa Creu i Sant Pau, Dept Med Oncol, Barcelona, Spain

[5] Oncoclin Inst Res & Educ, Dept Educ & Res, Rio De Janeiro, Brazil

[6] Wake Forest Univ, Dept Hematol & Oncol, Sch Med, Winston Salem, NC USA

[7] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain

[8] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain

[9] Hosp Sirio Libanes, Ctr Oncol, Ctr Oncol Asa Sul, Brasilia, DF, Brazil

[10] Fox Chase Canc Ctr, Dept Hematol Oncol, Main Campus, Philadelphia, PA USA

[11] Ist Clin Humanitas, Dept Med Oncol, Rozzano, Italy

[12] Davidoff Canc Ctr, Rabin Med Ctr, Thorac Canc Serv, Petah Tiqwa, Israel

[13] Osped S Maria Misericordia, Dept Med Oncol, Perugia, Italy

[14] Ironwood Canc & Res Ctr, Dept Hematol & Med Oncol, Chandler, AZ USA

[15] Hosp Univ Son Espases, Dept Med Oncol, Palma de Mallorca, Spain

[16] Amgen Inc, Thousand Oaks, CA USA

[17] Sackler Sch Med, Div Oncol, Meir Med Ctr, Oncol Serv, Rishon Leziyyon, Israel

[18] Univ Torino Orbassano, Dept Oncol, Orbassano, Italy

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PP01.17

引用

页码：E17 / E17

页数：1

共 50 条

[1] Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)
Awad, M.
Pelizzari, G.
Stevenson, J. P.
Majem Tarruella, M.
Ferreira, C. G. M.
Petty, W. J.
Arriola, E.
de Castro, J.
Morbeck, I.
Bauman, J. R.
Toschi, L.
Zer, A.
Metro, G.
Kalmadi, S.
Azkarate Martinez, A.
Xia, C.
Meloni, A.
Obiozor, C.
Maimon, N.
Novello, S.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1005 - S1005
[2] Sotorasib in KRAS p.G12C-mutated NSCLC
Gassa, Asmae
Oezkan, Filiz
Bruns, Christiane
Schmidt, Thomas
Alakus, Hakan
ONKOLOGE, 2021, 27 (10): : 1031 - 1032
[3] Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program
Reale, M. L.
Passiglia, F.
Brambilla, M.
Pasello, G.
Minuti, G.
Bulotta, A.
Pizzutilo, P.
Sini, C.
Costa, J.
Roca, E.
Bria, E.
Pilotto, S.
Genova, C.
Metro, G.
Citarella, F.
Bordi, P.
Russo, A.
Chiari, R.
Andrikou, K.
Novello, S.
ANNALS OF ONCOLOGY, 2023, 34
[4] Sotorasib for KRAS p.G12C-mutated advanced pancreatic cancer
Baker, Holly
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (03): : 213 - 213
[5] Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
Strickler, J. H.
Satake, H.
George, T. J.
Yaeger, R.
Hollebecque, A.
Garrido-Laguna, I.
Schuler, M.
Burns, T. F.
Coveler, A. L.
Falchook, G. S.
Vincent, M.
Sunakawa, Y.
Dahan, L.
Bajor, D.
Rha, S. -Y.
Lemech, C.
Juric, D.
Rehn, M.
Ngarmchamnanrith, G.
Jafarinasabian, P.
Tran, Q.
Hong, D. S.
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (01): : 33 - 43
[6] Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100
Ramalingam, S.
Skoulidis, F.
Govindan, R.
Velcheti, V.
Li, B.
Besse, B.
Dy, G.
Kim, D.
Schuler, M.
Vincent, M.
Wilson, F.
Park, J.
Gutierrez, J.
Tran, Q.
Jones, S.
Wolf, J.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1123 - S1123
[7] Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
Schmidt, Jonas Frederik
Entz, Dominik
Brasch, Frank
Goerner, Martin
CASE REPORTS IN ONCOLOGY, 2024, 17 (01): : 1019 - 1024
[8] Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib
Skoulidis, F.
Schuler, M.
Wolf, J.
Barlesi, F.
Price, T.
Dy, G.
Govindan, R.
Borghaei, H.
Falchook, G.
Li, B.
Ramalingam, S.
Sacher, A.
Spira, A.
Takahashi, T.
Anderson, A.
Ang, A.
Dai, T.
Flesher, D.
Cifuentes, P.
Velcheti, V.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S929 - S930
[9] Assessing the safety profile of sotorasib in KRAS G12C-mutated advanced NSCLC
Reactions Weekly, 2025, 2045 (1) : 6 - 6
[10] Long-Term Outcomes with Sotorasib in KRAS G12cMutated Advanced NSCLC from the Global Expanded Access Program (EAP) Study-436
Novello, S.
Maimon, N.
Stevenson, J.
Petty, W.
Ferreira, C. G.
Morbeck, I.
Zer, A.
Bauman, J.
Kalmadi, S.
Xia, C.
Meloni, A. R.
Mehta, B.
Ardito-Abraham, C.
Kormany, W.
Awad, M.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S352 - S353

← 1 2 3 4 5 →